NCT05951777 is the identifier for one clinical trial record on ClinicalTrials.gov. It lists a Phase 2 study of autologous adipose-derived cells in chronic traumatic brain injury, sponsor Hope Biosciences LLC, status recruiting, 51 estimated enrollment. This article explains what those fields mean and what a listing does not prove.
TLDR NCT05951777 is a registry record, not a result. It lists a Phase 2 study of autologous adipose-derived mesenchymal stem cells in chronic traumatic brain injury, sponsor Hope Biosciences LLC, status recruiting, 51 estimated enrollment. Recruiting means a study is enrolling, not that anything works. No adipose-derived product is FDA approved, and banking adipose tissue does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including traumatic brain injury. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for traumatic brain injury. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Marketing copy quotes NCT numbers as if they settle a question. They do not. A registry record describes a study plan and its current administrative status.
FDA states the limit plainly on its patient information page: “The inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.”
What the NCT05951777 record says
The record describes a Phase 2 study of HB-adMSC, autologous adipose-derived mesenchymal stem cells, in chronic traumatic brain injury. Hope Biosciences LLC is the sponsor. Status reads recruiting, enrollment reads 51 estimated, and the study is located in the United States. Anyone can open the study record and check.
Those fields describe a plan, not an outcome. The record carries no posted results. Quote the phase field itself, not a secondhand summary.
What a clinical trial listing is not
A listing is not evidence, and it is not FDA approval. No adipose-derived product is FDA approved for any disease, and the agency roster of approved cellular therapies lists none.
Many listings never finish, as our adipose trial landscape page shows. In one strict registry search of 169 United States records involving adipose-derived cells or tissue, 75, about 44 percent, were withdrawn, terminated, suspended, or of unknown status.
What recruiting and Phase 2 actually mean
Recruiting means the study is enrolling participants. It does not mean the intervention is effective, available, or approved. Status describes where a study sits in its own process, not what the study has shown.
Phase 2 means effectiveness is still being evaluated. 21 CFR 312.21 defines Phase 2 as “the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.”
FDA’s clinical research page puts Phase 2 at up to several hundred people with the condition, several months to 2 years, and approximately 33 percent advancing to the next phase. See our guide to trial phases.
How to read any registry listing
Each field answers one narrow question and leaves a second one open. The table applies that here.
| Field | This record | What it does not say |
|---|---|---|
| Condition | Traumatic brain injury | That anyone benefited |
| Intervention | Autologous adipose-derived cells | That it is approved |
| Phase | Phase 2 | That effectiveness is settled |
| Status | Recruiting | That anything is available |
| Enrollment | 51 estimated | That 51 people finished |
| Results | None posted | That outcomes are known |
Ask those six questions of any listing. The registry glossary lists five phases plus a Not Applicable label for trials without FDA-defined phases.
Why this record changes nothing about banking
Nothing in a registry record connects preserved tissue to a therapy. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit.
The FDA consumer alert states that no regenerative medicine products are approved for neurological disorders. Save My Fat preserves a patient’s own adipose tissue, and any future use depends on FDA regulatory status and physician guidance.
Frequently Asked Questions
Is NCT05951777 a Phase 2a trial?
No. The registry lists it as Phase 2. Phase 2 studies are run to evaluate effectiveness in people who have the condition under study, so the effectiveness question is still open.
Does a recruiting status mean the therapy is available?
No. Recruiting means a study is enrolling under its own protocol. It is not an offer to the public and it is not FDA approval. Adipose-derived cell work remains investigational and early stage. Ask a licensed provider about any medical decision.
Who sponsors this study, and how do I verify it?
The record names Hope Biosciences LLC as the sponsor. Open the registry entry, read the condition, intervention, phase, status, enrollment, and results fields, and compare them against any summary you were handed. The record governs.
Key Takeaways
NCT05951777 is a registry record for a Phase 2 study of autologous adipose-derived cells in chronic traumatic brain injury, sponsored by Hope Biosciences LLC, status recruiting, 51 estimated enrollment. Recruiting means enrolling. Phase 2 means effectiveness is still being evaluated. The record carries no posted results. FDA says a database listing does not mean a product is legally marketed, and no adipose-derived product is FDA approved for any disease. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit, and medical decisions belong with a licensed clinician.
Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can compare options on the pricing page or ask questions through the contact page.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: adipose stem cell trials.
